Monoclonal Antibody for Asthma and COPD Market Report 2025
Global Info Research‘s report offers an in-depth look into the current and future trends in Monoclonal Antibody for Asthma and COPD, making it an invaluable resource for businesses involved in the sector. This data will help companies make informed decisions on research and development, product design, and marketing strategies. It also provides insights into Monoclonal Antibody for Asthma and COPD’ cost structure, raw material sources, and production processes. Additionally, it offers an understanding of the regulations and policies that are likely to shape the future of the industry. In essence, our report can help you stay ahead of the curve and better capitalize on industry trends.
According to our (Global Info Research) latest study, the global Monoclonal Antibody for Asthma and COPD market size was valued at US$ 33094 million in 2024 and is forecast to a readjusted size of USD 48538 million by 2031 with a CAGR of 5.5% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Monoclonal antibodies for asthma and COPD are biologic agents targeting specific inflammatory pathways, neutralizing particular cytokines or receptors to modulate immune responses and improve airway inflammation and function. Representative drugs include Omalizumab, Mepolizumab, and Benralizumab, primarily used for the long-term management of patients with severe asthma, eosinophilic asthma, and certain COPD phenotypes. Upstream raw materials consist of high-purity recombinant antibody proteins, mammalian expression systems such as CHO cells, recombinant gene fragments, and associated buffers and excipients. Leading global suppliers include Biogen, Genentech (Roche), Amgen, GlaxoSmithKline (GSK), AstraZeneca, and Novartis, all of which possess advanced capabilities in antibody expression, purification, and large-scale manufacturing.
Downstream customers mainly comprise global pharmaceutical companies, hospitals, specialty clinics, and retail pharmacies, targeting patients with chronic respiratory diseases requiring long-term treatment. The primary end-users are patients with moderate-to-severe asthma or specific COPD phenotypes, as well as specialized respiratory medical institutions. With continuous advancements in biopharmaceutical technology and precision medicine, monoclonal antibody therapies are optimized for efficacy and safety, simultaneously driving upstream and downstream sectors, including expression system development, purification and fill-finish processes, cold-chain logistics, and clinical management services, thereby forming a complete high-value industrial ecosystem.
In 2024, the global average price of monoclonal antibodies for asthma and COPD is approximately USD 1,031 per vial, with total sales reaching about 31.2 million vials.
This report is a detailed and comprehensive analysis for global Monoclonal Antibody for Asthma and COPD market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Our Monoclonal Antibody for Asthma and COPD Market report is a comprehensive study of the current state of the industry. It provides a thorough overview of the market landscape, covering factors such as market size, competitive landscape, key market trends, and opportunities for future growth. It also pinpoints the key players in the market, their strategies, and offerings.
According to our (Global Info Research) latest study, the global Monoclonal Antibody for Asthma and COPD market size was valued at US$ 33094 million in 2024 and is forecast to a readjusted size of USD 48538 million by 2031 with a CAGR of 5.5% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Monoclonal antibodies for asthma and COPD are biologic agents targeting specific inflammatory pathways, neutralizing particular cytokines or receptors to modulate immune responses and improve airway inflammation and function. Representative drugs include Omalizumab, Mepolizumab, and Benralizumab, primarily used for the long-term management of patients with severe asthma, eosinophilic asthma, and certain COPD phenotypes. Upstream raw materials consist of high-purity recombinant antibody proteins, mammalian expression systems such as CHO cells, recombinant gene fragments, and associated buffers and excipients. Leading global suppliers include Biogen, Genentech (Roche), Amgen, GlaxoSmithKline (GSK), AstraZeneca, and Novartis, all of which possess advanced capabilities in antibody expression, purification, and large-scale manufacturing.
Downstream customers mainly comprise global pharmaceutical companies, hospitals, specialty clinics, and retail pharmacies, targeting patients with chronic respiratory diseases requiring long-term treatment. The primary end-users are patients with moderate-to-severe asthma or specific COPD phenotypes, as well as specialized respiratory medical institutions. With continuous advancements in biopharmaceutical technology and precision medicine, monoclonal antibody therapies are optimized for efficacy and safety, simultaneously driving upstream and downstream sectors, including expression system development, purification and fill-finish processes, cold-chain logistics, and clinical management services, thereby forming a complete high-value industrial ecosystem.
In 2024, the global average price of monoclonal antibodies for asthma and COPD is approximately USD 1,031 per vial, with total sales reaching about 31.2 million vials.
This report is a detailed and comprehensive analysis for global Monoclonal Antibody for Asthma and COPD market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Our Monoclonal Antibody for Asthma and COPD Market report is a comprehensive study of the current state of the industry. It provides a thorough overview of the market landscape, covering factors such as market size, competitive landscape, key market trends, and opportunities for future growth. It also pinpoints the key players in the market, their strategies, and offerings.
Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)
https://www.globalinforesearch.com/reports/2961589/monoclonal-antibody-for-asthma-and-copd
https://www.globalinforesearch.com/reports/2961589/monoclonal-antibody-for-asthma-and-copd
The research report encompasses the prevailing trends embraced by major manufacturers in the Monoclonal Antibody for Asthma and COPD Market, such as the adoption of innovative technologies, government investments in research and development, and a growing emphasis on sustainability. Moreover, our research team has furnished essential data to illuminate the manufacturer's role within the regional and global markets.
The research study includes profiles of leading companies operating in the Monoclonal Antibody for Asthma and COPD Market:
The report is structured into chapters, with an introductory executive summary providing historical and estimated global market figures. This section also highlights the segments and reasons behind their progression or decline during the forecast period. Our insightful Monoclonal Antibody for Asthma and COPD Market report incorporates Porter's five forces analysis and SWOT analysis to decipher the factors influencing consumer and supplier behavior.
The research study includes profiles of leading companies operating in the Monoclonal Antibody for Asthma and COPD Market:
The report is structured into chapters, with an introductory executive summary providing historical and estimated global market figures. This section also highlights the segments and reasons behind their progression or decline during the forecast period. Our insightful Monoclonal Antibody for Asthma and COPD Market report incorporates Porter's five forces analysis and SWOT analysis to decipher the factors influencing consumer and supplier behavior.
Segmenting the Monoclonal Antibody for Asthma and COPD Market by application, type, service, technology, and region, each chapter offers an in-depth exploration of market nuances. This segment-based analysis provides readers with a closer look at market opportunities and threats while considering the political dynamics that may impact the market. Additionally, the report scrutinizes evolving regulatory scenarios to make precise investment projections, assesses the risks for new entrants, and gauges the intensity of competitive rivalry.
Major players covered: Teva Pharmaceuticals、 Sanofi、 AstraZeneca、 GlaxoSmithKline、 Roche、 Amgen、 Abacus Medicine、 Swixx Biopharma、 OriFarm、 Aphria、 Novartis
Monoclonal Antibody for Asthma and COPD Market by Type: Reslizumab、 Dupilumab、 Benralizumab、 Mepolizumab、 Tezepelumab-ekko、 Omalizumab、 Others
Monoclonal Antibody for Asthma and COPD Market by Application: Hospital、 Clinic、 Others
Key Profits for Industry Members and Stakeholders:
Major players covered: Teva Pharmaceuticals、 Sanofi、 AstraZeneca、 GlaxoSmithKline、 Roche、 Amgen、 Abacus Medicine、 Swixx Biopharma、 OriFarm、 Aphria、 Novartis
Monoclonal Antibody for Asthma and COPD Market by Type: Reslizumab、 Dupilumab、 Benralizumab、 Mepolizumab、 Tezepelumab-ekko、 Omalizumab、 Others
Monoclonal Antibody for Asthma and COPD Market by Application: Hospital、 Clinic、 Others
Key Profits for Industry Members and Stakeholders:
1. The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period.
2. Which regulatory trends at corporate-level, business-level, and functional-level strategies.
3. Which are the End-User technologies being used to capture new revenue streams in the near future.
4. The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
5. One can increase a thorough grasp of market dynamics by looking at prices as well as the actions of producers and users.
6 Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
2. Which regulatory trends at corporate-level, business-level, and functional-level strategies.
3. Which are the End-User technologies being used to capture new revenue streams in the near future.
4. The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
5. One can increase a thorough grasp of market dynamics by looking at prices as well as the actions of producers and users.
6 Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Monoclonal Antibody for Asthma and COPD product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Monoclonal Antibody for Asthma and COPD, with price, sales, revenue and global market share of Monoclonal Antibody for Asthma and COPD from 2020 to 2025.
Chapter 3, the Monoclonal Antibody for Asthma and COPD competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Monoclonal Antibody for Asthma and COPD breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2020 to 2024.and Monoclonal Antibody for Asthma and COPD market forecast, by regions, type and application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibody for Asthma and COPD.
Chapter 14 and 15, to describe Monoclonal Antibody for Asthma and COPD sales channel, distributors, customers, research findings and conclusion.
About Us:
Global Info Research
Web: https://www.globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
US: 001-347 966 1888
Email: report@globalinforesearch.com
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Chapter 1, to describe Monoclonal Antibody for Asthma and COPD product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Monoclonal Antibody for Asthma and COPD, with price, sales, revenue and global market share of Monoclonal Antibody for Asthma and COPD from 2020 to 2025.
Chapter 3, the Monoclonal Antibody for Asthma and COPD competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Monoclonal Antibody for Asthma and COPD breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2020 to 2024.and Monoclonal Antibody for Asthma and COPD market forecast, by regions, type and application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibody for Asthma and COPD.
Chapter 14 and 15, to describe Monoclonal Antibody for Asthma and COPD sales channel, distributors, customers, research findings and conclusion.
About Us:
Global Info Research
Web: https://www.globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
US: 001-347 966 1888
Email: report@globalinforesearch.com
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
